Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.

Informe acción SZSE:301096

Capitalización de mercado: CN¥4.3b

Hangzhou Bio-Sincerity Pharma-TechLtd Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Hangzhou Bio-Sincerity Pharma-TechLtd has been growing earnings at an average annual rate of 34.7%, while the Life Sciences industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 39.9% per year. Hangzhou Bio-Sincerity Pharma-TechLtd's return on equity is 7.7%, and it has net margins of 20.7%.

Información clave

34.7%

Tasa de crecimiento de los beneficios

28.0%

Tasa de crecimiento del BPA

Crecimiento de la industria Life Sciences 26.8%
Tasa de crecimiento de los ingresos39.9%
Rentabilidad financiera7.7%
Margen neto20.7%
Última actualización de beneficios30 Sep 2024

Actualizaciones de resultados anteriores recientes

Solid Earnings May Not Tell The Whole Story For Hangzhou Bio-Sincerity Pharma-TechLtd (SZSE:301096)

Apr 29
Solid Earnings May Not Tell The Whole Story For Hangzhou Bio-Sincerity Pharma-TechLtd (SZSE:301096)

Recent updates

Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (SZSE:301096) Soars 30% But It's A Story Of Risk Vs Reward

Sep 30
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (SZSE:301096) Soars 30% But It's A Story Of Risk Vs Reward

Market Cool On Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.'s (SZSE:301096) Earnings Pushing Shares 27% Lower

Jul 24
Market Cool On Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.'s (SZSE:301096) Earnings Pushing Shares 27% Lower

Solid Earnings May Not Tell The Whole Story For Hangzhou Bio-Sincerity Pharma-TechLtd (SZSE:301096)

Apr 29
Solid Earnings May Not Tell The Whole Story For Hangzhou Bio-Sincerity Pharma-TechLtd (SZSE:301096)

Should You Be Adding Hangzhou Bio-Sincerity Pharma-TechLtd (SZSE:301096) To Your Watchlist Today?

Mar 14
Should You Be Adding Hangzhou Bio-Sincerity Pharma-TechLtd (SZSE:301096) To Your Watchlist Today?

Desglose de ingresos y gastos

Cómo gana y gasta dinero Hangzhou Bio-Sincerity Pharma-TechLtd. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

SZSE:301096 Ingresos, gastos y beneficios (CNY Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
30 Sep 241,025212120321
30 Jun 241,119287172298
31 Mar 241,072287156260
31 Dec 231,017272159240
30 Sep 23900250155203
30 Jun 23786229153184
31 Mar 23673210131164
01 Jan 23607194113163
30 Sep 2257319293149
30 Jun 2247915575120
31 Mar 2242512670110
31 Dec 213741116278
30 Sep 213041015151
30 Jun 21267854844
31 Mar 21211554636
31 Dec 20207575032
31 Dec 19156443515
31 Dec 1882112312
31 Dec 1726-7108
30 Jun 17308110
31 Mar 17275110
31 Dec 16243120
30 Sep 16211120
30 Jun 1616-1110
31 Mar 1616280
01 Jan 1616540
31 Dec 146-240

Ingresos de calidad: 301096 has a high level of non-cash earnings.

Margen de beneficios creciente: 301096's current net profit margins (20.7%) are lower than last year (27.8%).


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: 301096's earnings have grown significantly by 34.7% per year over the past 5 years.

Acelerando crecimiento: 301096's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Beneficios vs. Industria: 301096 had negative earnings growth (-15.3%) over the past year, making it difficult to compare to the Life Sciences industry average (-14.4%).


Rentabilidad financiera

Alta ROE: 301096's Return on Equity (7.7%) is considered low.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado